Advertisement

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Jan
19
Today In Oncology
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
HCC LLM Advice and Treatment Concordance
Can a Genetic Variant Affect the Efficacy of Abiraterone
Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo